Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells 111,313 Shares of Company Stock

November 6, 2026 by InsiderTrades.com

Key Points

Major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares at an average $29.89, worth about $3.33 million, reducing its ownership by 41.18% to 158,967 shares. The sale followed multiple recent share disposals; the filing did not state a reason.
Alamar reported quarterly revenue of $33.55 million and a loss of $0.19 per share, narrower than analysts expected. The company also raised its 2026 revenue outlook to $121 million–$123 million.
Analyst views are mixed: four rate the stock Buy, two Hold and one Sell, for a consensus Hold rating and a $33 target price.

Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of the company's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $29.89, for a total transaction of $3,327,145.57. Following the completion of the sale, the insider directly owned 158,967 shares in the company, valued at $4,751,523.63. This trade represents a 41.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20.
On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28.
On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.

Alamar Biosciences Stock Down 1.8%

Shares of ALMR stock opened at $26.91 on Friday. Alamar Biosciences, Inc. has a 52-week low of $18.84 and a 52-week high of $39.61. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.87 billion and a PE ratio of -13.73. The company has a 50-day moving average of $30.24.

Alamar Biosciences (NASDAQ:ALMR - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. Sell-side analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ALMR shares. Stifel Nicolaus upped their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Weiss Ratings cut shares of Alamar Biosciences from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, October 23rd. TD Cowen lifted their target price on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an "overweight" rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Alamar Biosciences currently has a consensus rating of "Hold" and a consensus target price of $33.00.

View Our Latest Stock Analysis on ALMR

Trending Headlines about Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68%, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Q3 revenue and guidance
Positive Sentiment: Alamar and GSK are collaborating on a large-scale proteomics study using Alamar’s platform. The research could increase the platform’s visibility, though no financial terms were disclosed. Alamar and GSK study
Positive Sentiment: Analysts raised their price targets: TD Cowen lifted its target to $36 and maintained a Buy rating, while BofA Securities raised its target to $35 from $31. These moves indicate improved analyst expectations, though targets are not guarantees. TD Cowen price target BofA Securities price target
Neutral Sentiment: The company plans to participate in upcoming investor conferences; the announcement did not include new financial guidance or other material business updates. Investor conferences announcement
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares on Nov. 3, after selling 43,930 shares on Nov. 2. The repeated sales—and the reduction in its reported ownership—could add supply and pressure sentiment; the filings do not give a reason for the sales. SEC filing on shareholder sale

Institutional Investors Weigh In On Alamar Biosciences

A number of institutional investors have recently modified their holdings of ALMR. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alamar Biosciences in the 3rd quarter valued at about $196,000. Squarepoint Ops LLC acquired a new position in Alamar Biosciences in the 2nd quarter worth about $283,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company's stock worth $2,280,000 after purchasing an additional 10,461 shares during the period. State Street Corp purchased a new position in Alamar Biosciences during the second quarter worth approximately $3,930,000. Finally, Wellington Management Group LLP purchased a new position in Alamar Biosciences during the second quarter worth approximately $12,407,000.

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.